{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:02:10Z","timestamp":1790017330971,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The youth funding of The People\u2019s Hospital of Guangxi Zhuang Autonomous Region","award":["QN2018-12"],"award-info":[{"award-number":["QN2018-12"]}]},{"name":"Self-financed Research Program of Health and Family Planning Commission of Guangxi Zhuang Autonomous Region","award":["Z20180722"],"award-info":[{"award-number":["Z20180722"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160589"],"award-info":[{"award-number":["82160589"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nanning Qingxiu District Science and Technology Bureau key research and development plan","award":["2020035"],"award-info":[{"award-number":["2020035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97160-7","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:59:33Z","timestamp":1745319573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study"],"prefix":"10.1038","volume":"15","author":[{"given":"Siyang","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangsong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanquan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"3","key":"97160_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"97160_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ijc.32723","volume":"147","author":"JL Petrick","year":"2020","unstructured":"Petrick, J. L. et al. International trends in hepatocellular carcinoma incidence, 1978\u20132012. Int. J. Cancer 147(2), 317\u2013330 (2020).","journal-title":"Int. J. Cancer"},{"issue":"2","key":"97160_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/jpm12020149","volume":"12","author":"D Galun","year":"2022","unstructured":"Galun, D. et al. Precision medicine for hepatocellular carcinoma: Clinical perspective. J. Pers. Med. 12(2), 149 (2022).","journal-title":"J. Pers. Med."},{"issue":"12","key":"97160_CR4","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.4254\/wjh.v13.i12.2039","volume":"13","author":"JC Ahn","year":"2021","unstructured":"Ahn, J. C., Qureshi, T. A., Singal, A. G., Li, D. & Yang, J. D. Deep learning in hepatocellular carcinoma: Current status and future perspectives. World J. Hepatol. 13(12), 2039\u20132051 (2021).","journal-title":"World J. Hepatol."},{"key":"97160_CR5","doi-asserted-by":"publisher","first-page":"747950","DOI":"10.3389\/fonc.2021.747950","volume":"11","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. Surgery after conversion therapy with PD-1 inhibitors plus tyrosine kinase inhibitors are effective and safe for advanced hepatocellular carcinoma: A pilot study of ten patients. Front. Oncol. 11, 747950 (2021).","journal-title":"Front. Oncol."},{"issue":"4","key":"97160_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng, A. L. et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76(4), 862\u2013873 (2022).","journal-title":"J. Hepatol."},{"issue":"7","key":"97160_CR7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2\u20133 study. Lancet Oncol. 22(7), 977\u2013990 (2021).","journal-title":"Lancet Oncol."},{"issue":"4","key":"97160_CR8","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu, J. et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label Phase II trail. Clin. Cancer Res. 27(4), 1003\u20131011 (2021).","journal-title":"Clin. Cancer Res."},{"key":"97160_CR9","unstructured":"Translational Therapy Collaboration Group, Liver Cancer Professional Committee, Chinese Anticancer Association. Chinese expert consensus on conversion therapy for liver cancer (2021 edition). Chin. J. Dig. Surg. 20(06), 600\u2013616 (2021)."},{"issue":"20","key":"97160_CR10","doi-asserted-by":"publisher","first-page":"e25749","DOI":"10.1097\/MD.0000000000025749","volume":"100","author":"H Linye","year":"2021","unstructured":"Linye, H. et al. Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis. Medicine (Baltimore) 100(20), e25749 (2021).","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"97160_CR11","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1158\/0008-5472.CAN-21-4260","volume":"82","author":"YT Wei","year":"2022","unstructured":"Wei, Y. T. et al. Thymosin \u03b1-1 reverses M2 polarization of tumor-associated macrophages during efferocytosis. Cancer Res. 82(10), 1991\u20132002 (2022).","journal-title":"Cancer Res."},{"issue":"sup1","key":"97160_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/14712598.2018.1494717","volume":"18","author":"R Danielli","year":"2018","unstructured":"Danielli, R. et al. Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: Investigating immune checkpoints synergy. Expert Opin. Biol. Ther. 18(sup1), 77\u201383 (2018).","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"97160_CR13","doi-asserted-by":"publisher","first-page":"19711","DOI":"10.1038\/s41598-021-98937-2","volume":"11","author":"L Dai","year":"2021","unstructured":"Dai, L. et al. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma. Sci. Rep. 11(1), 19711 (2021).","journal-title":"Sci. Rep."},{"issue":"26","key":"97160_CR14","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J. Clin. Oncol. 38(26), 2960\u20132970 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"97160_CR15","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1007\/s00262-022-03185-6","volume":"71","author":"CJ Wu","year":"2022","unstructured":"Wu, C. J. et al. Lenvatinib plus pembrolizumab for systemic therapy-na\u00efve and -experienced unresectable hepatocellular carcinoma. Cancer Immunol. Immunother. 71(11), 2631\u20132643 (2022).","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"97160_CR16","first-page":"e677","volume":"2","author":"AR Kwilas","year":"2015","unstructured":"Kwilas, A. R., Donahue, R. N., Tsang, K. Y. & Hodge, J. W. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron. 2(1), e677 (2015).","journal-title":"Cancer Cell Microenviron."},{"issue":"3","key":"97160_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/cei.12069","volume":"172","author":"S Yasuda","year":"2013","unstructured":"Yasuda, S. et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin. Exp. Immunol. 172(3), 500\u2013506 (2013).","journal-title":"Clin. Exp. Immunol."},{"issue":"10126","key":"97160_CR18","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/S0140-6736(18)30208-3","volume":"391","author":"M Reig","year":"2018","unstructured":"Reig, M. & Bruix, J. Lenvatinib: Can a non-inferiority trial change clinical practice?. Lancet 391(10126), 1123\u20131124 (2018).","journal-title":"Lancet"},{"key":"97160_CR19","doi-asserted-by":"publisher","first-page":"100907","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang, K. et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade. Drug Resist. Updat. 66, 100907 (2023).","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"97160_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","volume":"7","author":"A Osipov","year":"2019","unstructured":"Osipov, A., Saung, M. T., Zheng, L. & Murphy, A. G. Small molecule immunomodulation: The tumor microenvironment and overcoming immune escape. J. Immunother. Cancer 7(1), 224 (2019).","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"97160_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14(7), 399\u2013416 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"97160_CR22","first-page":"506","volume":"65","author":"D Xiong","year":"2021","unstructured":"Xiong, D., Zhang, K. & Xu, M. Prognostic factors of nivolumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis. Panminerva Med. 65, 506\u2013510 (2021).","journal-title":"Panminerva Med."},{"issue":"1","key":"97160_CR23","doi-asserted-by":"publisher","first-page":"19711","DOI":"10.1038\/s41598-021-98937-2","volume":"11","author":"L Dai","year":"2021","unstructured":"Dai, L. et al. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma. Sci. Rep. 11(1), 19711 (2021).","journal-title":"Sci. Rep."},{"issue":"10","key":"97160_CR24","doi-asserted-by":"publisher","first-page":"e202000662","DOI":"10.26508\/lsa.202000662","volume":"3","author":"G Renga","year":"2020","unstructured":"Renga, G. et al. Thymosin \u03b11 protects from CTLA-4 intestinal immunopathology. Life Sci. Alliance 3(10), e202000662 (2020).","journal-title":"Life Sci. Alliance"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97160-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97160-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97160-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:59:38Z","timestamp":1745319578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97160-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97160"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97160-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of The People\u2019s Hospital of Guangxi Zhuang Autonomous Region and conducted in strict accordance with the principles of the Declaration of Helsinki. Due to the retrospective nature of the study, informed consent was waived. All patient-related data used in this study were de-identified and anonymized to protect privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}],"article-number":"13960"}}